NASDAQ:CRTX - Cortexyme Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
About
FAQ

Consensus Rating: Hold
Consensus Price Target: $27.00
Forecasted Upside: -53.97 %
Number of Analysts: 5
Breakdown:
2 Sell Ratings
1 Hold Ratings
2 Buy Ratings
0 Strong Buy Ratings

^$58.66 As of 06/24/2021 01:00 AM ET

▲ +1.55 (2.71%)

1 month | 3 months | 12 months

Get New Cortexyme Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for CRTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRTX

^$27.00

▼ -53.97% Downside Potential

This price target is based on 5 analysts offering 12 month price targets for Cortexyme in the last 3 months. The average price target is $27.00, with a high forecast of $34.00 and a low forecast of $20.00. The average price target represents a -53.97% upside from the last price of $58.66.

Current Consensus is Hold

The current consensus among 5 investment analysts is to hold stock in Cortexyme. This rating has held steady since November 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations Description Skip Past Price Target Consensus Chart

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

1/1/2020

0 strong buy ratings
2 buy ratings
0 hold ratings
1 sell ratings

Ratings as of

3/31/2020

0 strong buy ratings
2 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

6/29/2020

0 strong buy ratings
3 buy ratings
1 hold ratings
0 sell ratings

Ratings as of

9/27/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

12/26/2020

0 strong buy ratings
4 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

3/26/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

5/25/2021

0 strong buy ratings
3 buy ratings
1 hold ratings
2 sell ratings

Ratings as of

6/24/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/16/2021	Jefferies Financial Group	Downgrade	Buy ➝ Hold	$59.00 ➝ $34.00	Low
12/11/2020	Smith Barney Citigroup	Initiated Coverage	Sell		High
12/11/2020	Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell	Initiated Coverage	Sell	$20.00	High
12/7/2020	Bank of America	Upgrade	Neutral ➝ Buy		Medium
9/24/2020	Lifesci Capital	Reiterated Rating	Outperform		High
6/24/2020	HC Wainwright	Initiated Coverage	Buy	$76.00	High
6/2/2020	Jefferies Financial Group	Initiated Coverage	Buy	$59.00	Low
5/13/2020	Canaccord Genuity	Reiterated Rating	Buy	$42.00 ➝ $70.00	High
6/3/2019	Credit Suisse Group	Initiated Coverage	Underperform ➝ Underperform	$14.00	High
6/3/2019	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$42.00	High
6/3/2019	Bank of America	Initiated Coverage	Neutral ➝ Neutral	$28.00	High
6/3/2019	JMP Securities	Initiated Coverage	Mkt Outperform ➝ Mkt Outperform	$53.00	High

(Data available from 6/24/2016 forward)

Cortexyme, Inc., a clinical stage biopharmaceutical company, focuses on developing therapeutics for Alzheimer's disease and other degenerative disorders. Its lead drug candidate is atuzaginstat (COR388), an orally administered brain-penetrating small molecule gingipain inhibitor, which is in Phase II/III clinical trial for use in patients with mild to moderate Alzheimer's disease. Cortexyme, Inc. has a partnership with Parkinson Study Group. The company was incorporated in 2012 and is headquartered in South San Francisco, California.

Today's Range

Now: $58.66

$57.27

$60.72

50 Day Range

MA: $42.26

$33.46

$58.66

52 Week Range

Now: $58.66

$26.66

$60.72

Volume

183,050 shs

Average Volume

261,519 shs

Market Capitalization

$1.74 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.75

Frequently Asked Questions

What sell-side analysts currently cover shares of Cortexyme?

The following Wall Street sell-side analysts have issued stock ratings on Cortexyme in the last year: Bank of America Co., Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell, HC Wainwright, Jefferies Financial Group Inc., Lifesci Capital, Smith Barney Citigroup, and Zacks Investment Research.
View the latest analyst ratings for CRTX.

What is the current price target for Cortexyme?

3 Wall Street analysts have set twelve-month price targets for Cortexyme in the last year. Their average twelve-month price target is $43.33, suggesting a possible downside of 24.1%. HC Wainwright has the highest price target set, predicting CRTX will reach $76.00 in the next twelve months. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell has the lowest price target set, forecasting a price of $20.00 for Cortexyme in the next year.
View the latest price targets for CRTX.

What is the current consensus analyst rating for Cortexyme?

Cortexyme currently has 2 sell ratings, 1 hold rating and 3 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in CRTX, but not buy more shares or sell existing shares.
View the latest ratings for CRTX.

What other companies compete with Cortexyme?

Other companies that are similar to Cortexyme include Cerner, Omnicell, Allscripts Healthcare Solutions, Vocera Communications, HealthStream, Computer Programs and Systems, Athena Technology Acquisition and Mirage Energy.

How do I contact Cortexyme's investor relations team?

Cortexyme's physical mailing address is 269 EAST GRAND AVE, SOUTH SAN FRANCISCO CA, 94080. The biopharmaceutical company's listed phone number is (650) 910-5717 and its investor relations email address is [email protected] The official website for Cortexyme is www.cortexyme.com.